Multiple myeloma in New Zealand: surprising findings from linked administrative databases
Presented by Dr Richard Milne, from the University of Auckland, School of Pharmacy
When: Monday 3rd June, 12pm
Where: University of Technology Sydney CB05D.02.20
This seminar is free, just register by 31st May 2019. Please register at: https://www.eventbrite.com/e/chere-seminar-milne-tickets-62187365083
The incidence and prevalence of the blood cancer multiple myeloma are both increasing and survival is improving. Using linked national data from the New Zealand cancer registry, mortality register, pharmaceuticals collection and hospital admissions dataset, we evaluated the incidence, overall survival and cause-specific survival of individuals who were diagnosed with myeloma between January 2004 and December 2016; the impact of novel anti-myeloma agents on survival; and the annual cost burden. This seminar will report the findings.
Richard Milne PhD, MRSNZ is a private consultant in health technology assessment and Associate Professor in the School of Pharmacy at the University of Auckland. He has developed prospective economic models of novel interventions including pharmaceuticals, vaccines, medical devices and clinical programmes; also, real world evidence on the impact of novel interventions in New Zealand. Richard was founding Editor of PharmacoEconomics, a founding member of ISPOR and first President of ISPOR NZ.